Abstract:Abstract Despite evidence of clear benefit, genetic testing of pediatric oncology patients for germline variants remains rare due to a variety of factors, including insurance/financial barriers, limited knowledge about genetic testing, and competing interests for time and resources. Limited access to genetic testing, pre-test counseling and multidisciplinary care have been shown to disproportionately affect patients with limited resources. This represents a critical unmet need in pediatric oncology. Genetic testing station (GTS) is a pre-test counseling video tool that reviews what genetic testing is, why it might be indicated, and explains potential results. Similar video tools have been successfully used in other settings to increase rates of genetic testing, but there are no published reports on the effectiveness of a video education intervention to increase genetic testing in pediatric oncology patients. To test the effectiveness of GTS on genetic testing knowledge and feelings about genetic testing compared to in-person counseling, we use 5 previously validated tools pre- and post-intervention. The initial surveys measure genetic testing knowledge, decisional conflict, healthy literacy, evaluation of GTS and demographics. If participants complete genetic testing, we use the MICRA to assess the impact on their cancer risk assessment. Our GTS arm is recruited from UCLA Pediatric Sarcoma patients, and the in-person counseling arm is recruited from the UCLA Cancer Predisposition clinic. We have recruited 28 participants in the GTS arm and seven in the in-person counseling arm, of which 10 are patients over 18 years old, two are patients between 12-17 years old, and 23 are parents. In our GTS arm, there are 20 female and eight male participants. A majority identify as white or Latino. For the in-person counseling arm, there are four male and three female participants who identify as white, Middle Eastern, or Latino. A similar percentage score with high health literacy, 68% in the GTS arm and 71% for the in-person counseling arm. The majority of patients have no decisional conflict pre- or post-intervention for the GTS group, while the in-person counseling arm shows high initial decision conflict that is fully resolved with counseling. There is a statistically significant increase in genetic testing knowledge for five out of 10 questions comparing pre- and post-GTS. For GTS participants who have completed genetic testing and the MICRA, there is overall low distress and uncertainty, but higher scores for parents than adult or minor patients. In conclusion, there has been high interest in germline genetic testing in pediatric oncology patients with all families deciding to pursue genetic testing after viewing GTS. GTS is an effective tool in increasing genetic testing knowledge in participants. Therefore, GTS is a promising approach to increase access to genetic testing, while providing adequate pre-test counseling and no decisional conflict. Citation Format: Camille Hamilton, Mariana Niell Swiller, Franceska Bhansali, Alyssa Hoover, Stephanie Bottomley, Marisa Lewis, Bianca Russell, Julian A. Martinez, Beth Karlan, Noah Federman, Vivian Y. Chang. Genetic testing station increases access to germline genetic testing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6375.

Validation of a guidelines-based digital tool to assess the need for germline cancer genetic testing

Digital cancer genetic risk assessment in a gynecologic oncology clinic.

Improving feasibility and timeliness of hereditary cancer risk assessment with a brief patient-administered digital tool and rapidly available telehealth genetic counseling.

Standards-Based Clinical Decision Support Platform to Manage Patients Who Meet Guideline-Based Criteria for Genetic Evaluation of Familial Cancer

Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic

Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia

BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial

Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families Harboring BRCA1/BRAC2 Pathogenic Variants: A Web-Based Platform for Cascade Genetic Testing

Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery

Abstract 6375: Genetic testing station increases access to germline genetic testing

Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients

TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing

Outcomes of a universal germline screening program in a community urology practice

Abstract LB145: Implementing timely germline genetic testing for patients with pancreatic cancer via a point-of-care digital education and health assessment tool

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer

Timely targeted testing for hereditary cancer syndromes - Importance of clinician-facilitated cascade testing in the first year post-diagnosis

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Parents' and patients' perspectives, experiences, and preferences for germline genetic or genomic testing of children with cancer: A systematic review